SB-0107 / Sinopia Biosci - LARVOL DELTA

Sinopia Biosciences Publishes Preclinical Data in Science Translational Medicine Supporting SB-0110, a Novel PKA-II Modulator, for Parkinson’s Disease (The Manila Times) - "...anticipated first-in-human studies in 2027...In non-human primate (NHP) models of PD with established dyskinesia, SB-0107 and novel optimized derivatives, including SB-0110, significantly reduced dyskinesia severity while potentiating the antiparkinsonian benefits of levodopa; SB-0110 and SB-0107 demonstrated no meaningful activity across established Parkinson's drug targets, a large panel of GPCR targets, and an off-target safety-liability panel, supporting a differentiated mechanism with a favorable preclinical safety profile ahead of IND-enabling toxicology....The work further validates omics-guided discovery as an unbiased strategy for identifying differentiated therapeutic targets and drug candidates by capturing global cellular changes rather than focusing on preselected pathways or mechanisms."

First-in-human • New trial • Preclinical • Parkinson's Disease